SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra 3.0 system. This milestone procedure underscores the company's commitment to advancing robotic cardiac surgery in the region and demonstrates the system's versatility in complex cardiac procedures.
The expansion into cardiac surgery at a leading Indian hospital is significant because it showcases the SSi Mantra's capabilities beyond general surgery, potentially opening new clinical applications and markets for the company. As of September 8, SS Innovations reported 238 SSi Mantra systems installed, a 42% increase from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka, and the Philippines. This rapid adoption reflects growing global demand for affordable and advanced robotic surgical solutions.
"We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region," the company wrote in a LinkedIn post. "At SS Innovations International, Inc. we remain committed to enabling hospitals and..." The company's focus on expanding into new geographies and clinical areas is a key driver of its growth strategy.
SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand the SSi Mantra into additional international markets. These regulatory milestones are critical for entering major markets and could significantly accelerate the company's revenue growth. The successful cardiac procedure at HCG Hospital adds to the clinical evidence supporting the SSi Mantra's safety and efficacy, which is essential for regulatory approvals and physician adoption.
The launch of the robotic cardiac surgery program at HCG Hospital is more than a single clinical achievement; it signals the broader potential of the SSi Mantra to transform cardiac care in emerging markets where access to advanced surgical robotics has been limited. By enabling complex cardiac procedures with a cost-effective robotic system, SS Innovations is positioning itself to capture a share of the growing global robotic surgery market. The company's newsroom at https://ibn.fm/SSII provides the latest updates on SSII, and investors can read more about this announcement through Read More>>. For additional information about the company, visit SS Innovations International (NASDAQ: SSII).
InvestorWire, a specialized communications platform, distributed this news through its network, which includes a Dynamic Brand Portfolio and editorial syndication to 5,000+ outlets. Such broad dissemination ensures that significant developments like this reach a wide audience of investors and industry stakeholders. As SS Innovations continues to expand its global footprint, its progress in cardiac surgery and regulatory approvals will be key indicators of its long-term success. The company's ability to innovate and adapt its technology for diverse clinical needs will determine its competitive position in the evolving robotic surgery landscape.
